Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Notes Payables (2021 - 2024)

Summit Therapeutics (SMMT) has disclosed Notes Payables for 4 consecutive years, with $24.5 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Notes Payables fell 75.5% year-over-year to $24.5 million, compared with a TTM value of $24.5 million through Sep 2024, down 75.5%, and an annual FY2022 reading of $19.8 million, changed N/A over the prior year.
  • Notes Payables was $24.5 million for Q3 2024 at Summit Therapeutics, down from $100.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $100.0 million in Q3 2023 and bottomed at $19.8 million in Q4 2022.
  • Average Notes Payables over 4 years is $59.8 million, with a median of $55.0 million recorded in 2021.
  • Peak annual rise in Notes Payables hit 75.5% in 2024, while the deepest fall reached 75.5% in 2024.
  • Year by year, Notes Payables stood at $55.0 million in 2021, then crashed by 64.03% to $19.8 million in 2022, then surged by 405.82% to $100.0 million in 2023, then plummeted by 75.5% to $24.5 million in 2024.
  • Business Quant data shows Notes Payables for SMMT at $24.5 million in Q3 2024, $100.0 million in Q2 2024, and $100.0 million in Q3 2023.